KPG-121 in Castration Resistant Prostate Cancer

Condition: Prostate Cancer

Sponsor: Kangpu Biopharmaceuticals, Ltd.

KPG-121-101: Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

A study evaluating the addition of KPG-121 to treatment with enzalutamide, abiraterone, or apalutamide that has been ongoing for at least 4 weeks.

For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.